RXSTNasdaqOphthalmic GoodsFiscal year ends December 31
RxSight, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$4.69+0.18 (+3.99%)
Close on Oct 19, 2026
- Market cap
- $194.59M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$3.55 (−43.08%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
RxSight, Inc. saw revenue fall 13.2% to $127.58M over the twelve months to Jun 30, 2026. Free cash flow was -$27.17M.
Revenue
$127.58M
-13.2% vs. a year earlier
Operating income
-$55.11M
TTM Q2 2026
Free cash flow
-$27.17M
TTM Q2 2026
EPS, diluted
-$1.13
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $194.59M
- P/E ratio
- –
- Price to sales
- 1.53
- Price to book
- 0.74
- Dividend yield
- –
- Free cash flow yield
- -13.96%
Fundamentals
- Revenue
- $127.58M
- Net income
- -$46.95M
- EPS, diluted
- -$1.13
- Free cash flow
- -$27.17M
- Book value per share
- $6.35
- Diluted shares
- 41M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
$127.58M-13.2% YoY
Gross profit
$98.87M-8.0% YoY
Operating income
-$55.11M
Net income
-$46.95M
EPS, diluted
-$1.13
Free cash flow
-$27.17M
Reported periodTrailing twelve months